Follow us on LinkedIn Twitter


The shopping cart is empty
Knows our products
Knows our services
Knows our R+D

PROALT (Protein Alternatives SL)


ProAlt is young biotech company developing innovative products for colorectal cancer early diagnosis in blood and novel therapeutic antibodies for the treatment of colon, breast and melanoma metastatic tumors.


The company also offers its own manufactured recombinant proteins and antibodies, and different custom-tailored services in protein and antibodies design and manufacturing (CRO/CMO).

Special Offers

ProAlt news


PROALT announces partnership with Fusion Antibodies to develop humanized antibodies for therapy of metastatic colon cancer. View more



PROALT attends 11th Annual European Life Sciences CEO Forum & Exhibition for Partnering & Investing in Biotech & Pharma Industry. Zurich, (Switzerland) 26-27 february.View more


ProAlt events

May 2018

15th Anglonordic LifeScience Conference.

County Hall, London, UK. 24th May 2018.

View more




June 2018

BIO International Convention. Boston, MA (USA) 4-7 June 2018.

View more

ProAlt new products

PRO-50078 Human Beta-2-Microglobulin


PRO-50077, PRO-50076, PRO-50075 Human Gelsolin Isoform A (GSN) N- or C-terminal half

AB-10011 Rabbit anti-GSN polyclonal antibody

MAB-010, MAB-011 Mouse Anti-GSN monoclonal antibodies


PRO-50074, PRO-50073, Human Ganglioside GM2 activator isoform 1 (GM2AP) recombinant protein

AB-10010 Rabbit anti- GM2AP, polyclonal antibody

MAB-008, MAB-009: Mouse Anti-GM2AP monoclonal antibodies

© Developed by Web4Bio